Edwards Lifesciences market cap is $54.9 b, and annual revenue was $4.35 b in FY 2019

Edwards Lifesciences Net income (Q3, 2020)325.2 M

Edwards Lifesciences EBIT (Q3, 2020)357.8 M

Edwards Lifesciences revenue was $4.35 b in FY, 2019 which is a 16.8% year over year increase from the previous period.

Edwards Lifesciences revenue breakdown by business segment: 17.0% from Critical Care, 19.4% from Surgical Structural Heart, 63.0% from Transcatheter Aortic Valve Replacement and 0.6% from Other

Edwards Lifesciences revenue breakdown by geographic segment: 21.6% from Europe, 9.9% from Rest of World, 10.2% from Japan and 58.2% from United States

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Revenue | 3.4b | 3.7b | 4.3b |

| 8% | 17% | |

## Cost of goods sold | 875.3m | 939.4m | 1.1b |

## Gross profit | 2.6b | 2.8b | 3.2b |

| 75% | 75% | 74% |

## R&D expense | 552.6m | 622.2m | 752.7m |

## General and administrative expense | 984.7m | 1.1b | 1.2b |

## Operating expense total | 1.5b | 2.0b | 2.1b |

## EBIT | 748.2m | 1.1b | |

| 20% | 26% | |

## Interest expense | 23.2m | 29.9m | 20.7m |

## Interest income | 20.3m | 32.0m | 32.2m |

## Pre tax profit | 1.0b | 761.4m | 1.2b |

## Income tax expense | 451.3m | 39.2m | 119.6m |

## Net Income | 583.6m | 722.2m | 1.0b |

## EPS | 2.7 | 3.4 | 4.9 |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 894.8m | 943.7m | 906.6m | 993.0m | 1.1b | 1.1b | 1.1b | 1.1b | |

## Cost of goods sold | 233.6m | 246.2m | 224.9m | 231.8m | 304.0m | 292.4m | 265.1m | 238.2m | |

## Gross profit | 661.2m | 697.5m | 681.7m | 761.2m | 782.9m | 801.6m | 863.6m | ||

| 74% | 74% | 75% | 77% | 72% | 73% | 77% | ||

## R&D expense | 143.2m | 154.1m | 161.8m | 171.4m | 191.9m | 195.5m | 187.4m | 182.1m | 195.5m |

## General and administrative expense | 256.0m | 274.9m | 269.5m | 280.3m | 308.5m | 306.2m | 307.8m | 274.9m | 307.2m |

## Operating expense total | 408.7m | 445.4m | 432.8m | 487.0m | 515.4m | 507.3m | 505.5m | 856.5m | 502.1m |

## EBIT | 252.5m | 252.1m | 248.9m | 274.2m | 267.5m | 294.3m | 358.1m | (169.7m) | 357.8m |

| 28% | 27% | 27% | 28% | 25% | 27% | 32% | 31% | |

## Interest expense | 500.0k | 4.5m | 1.8m | 800.0k | |||||

## Interest income | 800.0k | 2.0m | 2.4m | 2.8m | |||||

## Pre tax profit | 263.5m | 251.0m | 248.7m | 278.0m | 271.3m | 301.7m | 364.5m | (168.2m) | 364.3m |

## Income tax expense | 56.9m | (31.7m) | 22.8m | 28.3m | 29.0m | 27.0m | 53.9m | (46.3m) | 39.1m |

## Net Income | 206.6m | 282.7m | 225.9m | 249.7m | 242.3m | 274.7m | 310.6m | (121.9m) | 325.2m |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Cash | 818.3m | 714.1m | 1.2b |

## Accounts Receivable | 421.6m | 456.9m | 543.6m |

## Prepaid Expenses | 60.6m | 54.3m | 59.1m |

## Inventories | 554.9m | 607.0m | 640.9m |

## Current Assets | 2.5b | 2.3b | 3.0b |

## PP&E | 679.7m | 867.5m | 1.1b |

## Goodwill | 1.1b | 1.1b | 1.2b |

## Total Assets | 5.7b | 5.3b | 6.5b |

## Accounts Payable | 116.6m | 134.0m | 180.4m |

## Short-term debt | 636.6m | 25.5m | |

## Current Liabilities | 1.4b | 876.6m | 902.4m |

## Long-term debt | 438.4m | 593.8m | 653.3m |

## Total Debt | 1.1b | 593.8m | 678.8m |

## Common Stock | 212.0m | 215.2m | 218.1m |

## Additional Paid-in Capital | 1.2b | 1.4b | 1.6b |

## Retained Earnings | 2.0b | 2.7b | 3.7b |

## Total Equity | 3.0b | 3.1b | 4.1b |

## Debt to Equity Ratio | 0.4 x | 0.2 x | 0.2 x |

## Debt to Assets Ratio | 0.2 x | 0.1 x | 0.1 x |

## Financial Leverage | 1.9 x | 1.7 x | 1.6 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Net Income | 583.6m | 722.2m | 1.0b |

## Depreciation and Amortization | 81.9m | 77.4m | 89.3m |

## Accounts Receivable | (3.9m) | (28.7m) | (88.0m) |

## Inventories | (124.0m) | (65.7m) | (105.4m) |

## Accounts Payable | 85.2m | 192.5m | (63.5m) |

## Cash From Operating Activities | 1.0b | 926.8m | 1.2b |

## Purchases of PP&E | (168.1m) | (238.7m) | (254.4m) |

## Cash From Investing Activities | (647.2m) | 76.7m | (595.8m) |

## Long-term Borrowings | (818.4m) | (1.1b) | (28.9m) |

## Cash From Financing Activities | (473.2m) | (1.1b) | (115.6m) |

## Net Change in Cash | (111.8m) | (104.2m) | 465.0m |

## Interest Paid | 19.9m | 30.1m | 19.9m |

## Income Taxes Paid | 143.7m | 223.7m | 61.5m |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 206.6m | 489.3m | 715.2m | 249.7m | 492.3m | 766.7m | 310.6m | 188.7m | 513.9m |

## Depreciation and Amortization | 19.1m | 38.3m | 57.5m | 20.6m | 42.3m | 65.4m | 24.5m | 74.6m | |

## Accounts Receivable | 29.9m | 2.6m | (300.0k) | (45.8m) | (89.2m) | (70.3m) | (4.2m) | 21.5m | (9.2m) |

## Inventories | (3.3m) | (20.5m) | (43.5m) | (29.4m) | (61.9m) | (83.9m) | (35.2m) | (99.2m) | (118.2m) |

## Accounts Payable | (118.0m) | (89.2m) | 4.0m | (242.2m) | (190.6m) | (109.2m) | (144.4m) | (135.3m) | (53.9m) |

## Cash From Operating Activities | 151.3m | 291.5m | 633.8m | 1.5m | 342.7m | 780.0m | 438.2m | 654.3m | |

## Purchases of PP&E | (43.2m) | (96.0m) | (181.1m) | (42.2m) | (106.8m) | (182.9m) | (82.2m) | (190.5m) | (293.8m) |

## Cash From Investing Activities | 220.3m | 325.2m | 71.0m | (49.5m) | (137.8m) | (150.5m) | (134.7m) | (144.9m) | (271.2m) |

## Long-term Borrowings | (5.1m) | (522.2m) | (524.1m) | (4.0m) | (20.2m) | (23.7m) | (8.2m) | (11.8m) | |

## Cash From Financing Activities | 40.9m | (199.8m) | (256.5m) | 44.4m | (187.0m) | (152.6m) | (586.4m) | (562.3m) | (528.3m) |

## Net Change in Cash | 408.7m | 408.1m | 443.0m | (4.9m) | 12.7m | 472.5m | (516.2m) | (275.6m) | (155.1m) |

## Income Taxes Paid | 195.1m | 227.3m | 45.2m | 53.9m |

USD | FY, 2017 |
---|---|

## EV/CFO | 24.1 x |

## Revenue/Employee | 281.6k |

## Debt/Equity | 0.4 x |

## Debt/Assets | 0.2 x |

## Financial Leverage | 1.9 x |

## P/E Ratio | 41.7 |